Gossamer bio to present clinical and preclinical data at the pulmonary vascular research institute 2025 annual congress

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced one oral and three poster presentations related to seralutinib at the pulmonary vascular research institute (pvri) 2025 annual congress taking place january 29th through febru.
GOSS Ratings Summary
GOSS Quant Ranking